235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1753)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- (-)
Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- (-) Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (49)
- Urology (4)
- Vascular Conditions (10)
Displaying 601 - 631 of 631
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents in treating patients with chronic lymphocytic leukemia (CLL).
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The overall purpose of this part of the study is to determine the best dose of JCAR017 for treating adult participants with relapsed or refractory B-cell Chronic Lymphocytic Leukemia (CLL), and Small Lymphocytic Lymphoma (SLL) and to understand the side effects that participants with your disease may have when they are treated with JCAR017.
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this research study is to determine the preliminary safety and effectiveness (how well something works) of alvocidib when used after the standard drug decitabine in patients with MDS. The study will also gain information about the PK (the process by which a drug is absorbed, distributed, metabolized and eventually eliminated by the body),…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find out if the study treatment called RO7198457 (PCV) can be safely given to patients with cancer. PCV is a personalized cancer vaccine. Participants will either received PCV alone or in combination with atezolizumab.
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
Epstein-Barr Virus (EBV) is the virus that causes mononucleosis, also known as mono. Almost all adults have had EBV. For most people, EBV never causes a health problem. However, when their immune system is not working properly (people who have had a transplant and those who have immune disorders), EBV can cause certain diseases where cells grow abnormally…
Condition: Cancer
Investigator: Alice Lee, MD
Status: Closed
The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United…
Condition: Cancer / Lymphoma
Investigator: Owen O'Connor, MD, PhD
Status: Closed
This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This is an open-label, Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) whose cancer has gotten worse on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study consists of a number of treatment cohorts to test the efficacy, safety, and tolerability of multiple…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental product, axicabtagene ciloleucel, in combination with either rituximab or lenalidomide is safe and effective in treating lymphoma. Kite Pharma, Inc., (Kite) is the sponsor of this study. The sponsor is funding this research study and has also designed the trial. The sponsor is testing an…
Condition: Psychiatric Disorders / Schizophrenia
Investigator: Guillermo Horga, MD, PhD
Status: Closed
In this study, we are trying to learn more about the symptoms of schizophrenia, specifically to learn how abnormalities in the brain may produce certain experiences that are common in patients with schizophrenia. The study involves clinical interviews, clinical chart review, computer tests, and magnetic resonance imaging (MRI) scans.
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This is a research study for a vaccine called GEN-009. The main purpose of this study is to obtain information on the safety of GEN-009 and how it may activate the immune system to fight cancer. GEN-009 is a personalized vaccine. Each vaccine is made specifically for each person in the study. The vaccine is made after taking and testing cells from your…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This is a cohort study looking at the effects of anastrozole (an aromatase inhibitor) on patients, and specifically at Aromatose Inhibitor Musculoskeletal Symptoms (AIMSS). The genetic predictors of AIMSS will also be evaluated. Participants will take daily anastrazole and will be followed for 12 months. The study will enroll 35 patients at Columbia…
Condition: Cancer
Investigator: Fabio Iwamoto, MD
Status: Closed
This clinical trial will investigate an experimental drug called FT-2102. FT-2102 targets tumor cells that have an abnormal gene (code that tells your body what proteins to make), called isocitrate dehydrogenase 1 (IDH1). Research subjects with either a Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic cholangiocarcinoma (IHCC), a Glioma, or…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess how safe and well tolerated study drugs, INCB24360 and nivolumab, are given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB24360 in combination with nivolumab works in preventing disease progression in patients with melanoma (MEL), non-small cell lung…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to determine if the study drug is safe and evaluate whether adjuvant therapy with the study drug will improve overall survival. The study drug is crizotinib (also known as XALKORI). The study will also collect tumor tissue and blood samples for future research.
Condition: Cancer / Solid Tumors
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an open-label, multicenter phase 1/2 study. The study is designed in two parts, the first is designed to evaluate the safety of the study drug ulocuplumab in combination with nivolumab in subjects with small cell lung cancer (SCLC) and pancreatic adenocarcinoma (PAC). Subjects will receive a low dose of ulocuplumab in combination with…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The purpose of this study is to look at a new treatment for non-muscle-invasive bladder cancer. This new form of paclitaxel, a drug currently used by injection into a vein to treat various types of cancer, is designed to be instilled (injected) into the urinary bladder with a catheter (tube) placed into your bladder through your urethra (the opening where…
Condition: Cancer
Investigator: Mark Frattini, MD, PhD
Status: Closed
The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on haematological cancer cells. BAY 1251152 works by obstructing a protein in your bodys cells called positive transcription elongation factor b (PTEFb) / cyclin-dependent kinase 9 (CDK9) pathway, which plays a role in the growth of…
Condition: Cancer / Breast Cancer
Investigator: Katherine Crew, MD
Status: Closed
To assess whether prophylactic beta blocker therapy with carvedilol compared with no intervention reduces the risk of subsequent cardiac dysfunction in patients with metastatic breast cancer receiving trastuzumab-based HER-2 targeted therapy.
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug sorafenib which works in a similar way to tivozanib. Tivozanib and sorafenib are both called study medication. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer. This study will…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to determine if REGN2810 (anti-PD-1) in combination with ipilimumab (anti-CTLA-4) plus initial platinum-based doublet chemotherapy, or REGN2810 in combination with ipilimumab will prolong how long you live without your disease progressing compared to the standard of care pembrolizumab (anti-PD-1) monotherapy treatment. Neither…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by…
Condition: Psychiatric Disorders / PTSD
Investigator: Yuval Neria, PhD
Status: Closed
Approximately half of the individuals with Post-traumatic Stress Disorder (PTSD) present with major depressive disorder (MDD). Compared to PTSD alone, patients with comorbid PTSD-MDD demonstrate greater distress and poorer treatment outcome. The goal of this pilot study is to collect preliminary data on the feasibility, safety, and initial efficacy of an…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to see if study drug AZD9291 is effective in treating non-small cell lung cancer (NSCLC) and if so, how it compares with chemotherapy. Only patients with NSCLC that has been confirmed as having the EGFR mutation are eligible to participate. Before patients can participate in the main study a tumor sample will be taken to check…
Condition: Cancer / Pancreatic Cancer
Investigator: Paul Oberstein, MD
Status: Closed
This research study is being conducted to see if a new treatment using a study drug called Olaparib given after platinum based chemotherapy treatments can reduce the risk of pancreatic cancer from growing back. Participants will receive either Olaparib or placebo (no contains active medication) and will stay on the research study for as long as they are not…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. The purpose of this study is to test any good and bad effects of a combination of study drugs called atezolizumab and bevacizumab. The combination of atezolizumab and bevacizumab could shrink your cancer but it…